Table 3.
Baseline characteristics of frozen embryo originating COS cycles.
| Ultra-long protocol | Long protocol | Antagonist protocol | Short group | P value | |
|---|---|---|---|---|---|
| No. of cycles | 98 | 101 | 54 | 52 | |
| Age, years | 33.00 (30.00,37.00)a | 31.00 (30.00,35.00)b | 33.00 (30.25,36.00)d | 37.00 (34.00,40.00)abd | <0.001 |
| BMI, kg/m2 | 23.14 (20.70,26.33)a | 23.28 (21.13,27.18) | 24.69 (23.01,26.17) | 25.33 (23.06,26.70)a | 0.016 |
| Duration of infertility, years | 3.00 (2.00,4.50) | 3.50 (1.50,4.00) | 3.50 (2.50,5.50) | 2.50 (2.00,4.00) | 0.084 |
| Primary infertility, n(%) | 51 (52.04)a | 50 (49.5)b | 25 (46.3)d | 7 (13.46)abd | <0.001 |
| AFC | 13.50 (10.00,19.75)a | 15.00 (11.00,20.00)b | 14.00 (9.00,28.5)d | 9.00 (5.75,12.00)abd | <0.001 |
| Basal FSH, IU/L | 6.08 (5.06,7.57) | 6.16 (5.61,7.03)b | 6.31 (5.92,7.71) | 6.87 (5.57,8.35)b | 0.013 |
| AMH, ng/ml | 2.84 (1.57,5.90)a | 4.17 (2.78,5.54)b | 4.09 (1.73,6.90)d | 1.35 (0.84,2.17)abd | <0.001 |
| Mean diameter of initial uterus, cm | 6.25 (5.50,7.30)c | 5.70 (4.70,6.75)c | 5.80 (4.76,7.05) | 5.80 (4.94,6.61) | 0.010 |
| History of dysmenorrhea | <0.001 | ||||
| None, n(%) | 15 (15.31) | 21 (20.79) | 15 (27.78) | 15 (28.85) | |
| Mild, n(%) | 21 (21.43) | 43 (42.57) | 13 (24.07) | 17 (32.69) | |
| Moderate, n(%) | 26 (26.53) | 13 (12.87) | 22 (40.74) | 9 (17.31) | |
| Severe, n(%) | 36 (36.73)f | 24 (23.76) | 4 (7.41)f | 11 (21.15) | |
| long-acting GnRHa pretreatment before FET | 0.004 | ||||
| yes | 62(63.26%)c | 39(38.61%)c | 27(50.00%) | 22(42.31%) | |
| no | 36(36.74%)c | 62(61.39%)c | 27(50.00%) | 30(57.7%) |
Data were presented as median (25th-75th percentile) for non-normality distribution variables and frequencies (percentages) for categorical variables.
BMI, body mass index; AFC, antral follicle count; FSH, follicle-stimulating hormone; AMH, anti-müllerian hormone; COS, controlled ovarian stimulation; FET, frozen embryo transplant.
aultra-long vs short; blong vs short; cultra-long vs long; dantagonist vs short; elong vs antagonist; fultra-long vs antagonist.